Truist Financial Issues Positive Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock Price

Key Points

• Truist raised its price target on BridgeBio to $102 (from $95) and maintained a "buy" rating, implying about a 45.42% upside from the stock's current level.
• Analyst sentiment is broadly positive—24 Buy vs. 1 Sell—giving a consensus "Moderate Buy" and a consensus price target of $87.71, below Truist's newer target.
• Despite positive analyst moves and a reported Vyndamax patent settlement with Pfizer that removes a legal overhang, BridgeBio remains unprofitable (Q last EPS of -$1.00 missed estimates) and analysts expect negative FY EPS (≈ -2.07).

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) had its price target upped by equities researchers at Truist Financial from $95.00 to $102.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Truist Financial's price objective would suggest a potential upside of 45.42% from the company's current price.

A number of other research analysts also recently issued reports on the company. TD Cowen reissued a "buy" rating on shares of BridgeBio Pharma in a research note on Monday, January 12th. Wells Fargo & Company raised their price objective on shares of BridgeBio Pharma from $88.00 to $98.00 and gave the stock an "overweight" rating in a research report on Friday, February 13th. Mizuho reissued an "outperform" rating and set a $106.00 target price on shares of BridgeBio Pharma in a research note on Tuesday. HC Wainwright reaffirmed a "buy" rating and issued a $100.00 price target on shares of BridgeBio Pharma in a research note on Monday. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of BridgeBio Pharma in a report on Wednesday, January 21st. Twenty-four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $87.71.

BridgeBio Pharma Price Performance

BBIO stock opened at $70.14 on Wednesday. BridgeBio Pharma has a 1 year low of $31.77 and a 1 year high of $84.94. The stock has a market cap of $13.73 billion, a price-to-earnings ratio of -18.58 and a beta of 1.09. The company has a 50 day simple moving average of $71.33 and a 200 day simple moving average of $70.84.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last issued its earnings results on Tuesday, February 24th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.25). The business had revenue of $154.18 million during the quarter, compared to analyst estimates of $150.71 million. The firm's quarterly revenue was up 2521.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.40) earnings per share. On average, equities research analysts anticipate that BridgeBio Pharma will post -2.07 EPS for the current fiscal year.

Insider Activity

In other BridgeBio Pharma news, Director Andrea Ellis sold 64,921 shares of the business's stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $64.87, for a total value of $4,211,425.27. Following the transaction, the director owned 18,589 shares of the company's stock, valued at approximately $1,205,868.43. The trade was a 77.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Maricel Apuli sold 510 shares of the firm's stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $74.31, for a total value of $37,898.10. Following the sale, the chief accounting officer directly owned 123,945 shares of the company's stock, valued at approximately $9,210,352.95. This represents a 0.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 237,084 shares of company stock worth $16,634,419. Corporate insiders own 18.20% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. QRG Capital Management Inc. increased its stake in shares of BridgeBio Pharma by 8.5% during the 1st quarter. QRG Capital Management Inc. now owns 7,174 shares of the company's stock worth $533,000 after purchasing an additional 564 shares during the last quarter. PFG Investments LLC boosted its holdings in BridgeBio Pharma by 41.7% in the 1st quarter. PFG Investments LLC now owns 7,725 shares of the company's stock worth $574,000 after buying an additional 2,275 shares during the period. Elevation Point Wealth Partners LLC purchased a new position in shares of BridgeBio Pharma in the first quarter valued at $243,000. Strs Ohio lifted its holdings in BridgeBio Pharma by 11.8% during the 1st quarter. Strs Ohio now owns 23,700 shares of the company's stock worth $1,760,000 after purchasing an additional 2,500 shares in the last quarter. Finally, Janney Montgomery Scott LLC boosted its position in shares of BridgeBio Pharma by 2.1% in the first quarter. Janney Montgomery Scott LLC now owns 26,143 shares of the company's stock valued at $1,941,000 after acquiring an additional 528 shares during the period. 99.85% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about BridgeBio Pharma

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: HC Wainwright raised its Q4 2026 EPS forecast to $0.02 (from -$0.31) and retains a "Buy" rating with a $100 target — a positive signal for late‑cycle upside expectations.
• Positive Sentiment: Mizuho reaffirmed an "outperform" rating and a $106 price target, implying meaningful upside from current levels. Mizuho reaffirms outperform, $106 PT
• Positive Sentiment: BridgeBio announced a settlement in the Vyndamax patent dispute with Pfizer, which removes a legal overhang that had created uncertainty around future revenue and competitive dynamics. BridgeBio gains after settlement in Pfizer Vyndamax patent dispute
• Neutral Sentiment: BridgeBio launched a health‑education initiative (features include high‑profile advocates); positive PR but limited near‑term revenue impact. BridgeBio launches health education effort
• Neutral Sentiment: Recent earnings transcripts and coverage provide detail on operations and pipeline execution, useful for investors but not a single catalyst. BridgeBio Q2 2025 Earnings Transcript
• Negative Sentiment: HC Wainwright lowered Q2 2026 EPS to ($0.64) from ($0.29) and trimmed FY2026 EPS slightly to ($1.77), flagging tougher near‑term results and pushing down short‑term expectations.
• Negative Sentiment: Analysts and previews (Zacks and others) flag the likelihood of negative Q1 earnings and note BBIO missed EPS in its most recent report — a reminder of cash burn and pipeline/timing risk that can pressure the stock. Zacks: Will BridgeBio report negative Q1 earnings?
• Negative Sentiment: Market headlines note heavy intraday swings (including an article about BBIO being on track for its worst session in months), reflecting investor uncertainty after the settlement and analyst moves. BBIO on track for worst day in 2.5 months

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio's pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.